Rezultati pretraživanja
  1. Geneticists solve a 15-year-old mystery surrounding a cluster of sudden deaths among Amish children, when they discovered they all were homozygous for a duplication in the RYR2 gene, which causes cardiac arrhythmic disorder

  2. Swiss drug company is contemplating a $4 million price tag on its gene therapy for type 1 spinal muscular atrophy, based on quality of life calculations

  3. 10. sij

    NatureBiotech: .23andMe out-licenses its first drug, an anti-inflammatory antibody, to Spanish biotech Almirall

  4. 25. ruj 2018.

    The Trump administration is going to review all fetal tissue research

  5. A recent FDA and USDA meeting offered no new ideas for labelling cell-based meats but biotechs made their opposition to term "lab-grown" known

  6. 26. lis 2018.

    Trump administration's newly announced drug pricing policy is met with skepticism by industry groups.

  7. 29. lis 2018.

    UK gene therapy biotech Orchard Therapeutics is set to go public, seeking greater than $1B valuation

  8. On the possibility of an extended shutdown

    Prikaži ovu nit
  9. Talk of drug pricing at Forbes Health Summitt has lamenting the present situation.

  10. Odgovor korisniku/ci

    “I thought we had a scientific evaluation system in place here, but clearly I was misguided.” - Alison Van Eenennaam

  11. Derek Lowe on FDA's about-face approval of Sarepta’s 2nd drug for muscular dystrophy (golodirsen) just months after sending the company a complete response letter, which enumerated multiple problems

  12. Senator Bernie Sanders threatens to create legislation to break patents for price gouging after BioMarin contemplates pricing its gene therapy for hemophilia

  13. ends a long standing agreement to supply rotovirus vaccine to West Africa. Pivots to Chinese market.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.